Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Free Cash Flow (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Free Cash Flow for 16 consecutive years, with $21.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 62.73% to $21.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $74.5 million, a 100.39% increase, with the full-year FY2025 number at $74.5 million, up 100.39% from a year prior.
  • Free Cash Flow was $21.4 million for Q4 2025 at Lemaitre Vascular, down from $26.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $26.5 million in Q3 2025 to a low of $149000.0 in Q1 2023.
  • A 5-year average of $9.7 million and a median of $8.4 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 96.43% in 2023, then soared 2383.89% in 2024.
  • Lemaitre Vascular's Free Cash Flow stood at $4.4 million in 2021, then crashed by 36.7% to $2.8 million in 2022, then skyrocketed by 236.07% to $9.5 million in 2023, then skyrocketed by 38.78% to $13.1 million in 2024, then surged by 62.73% to $21.4 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Free Cash Flow are $21.4 million (Q4 2025), $26.5 million (Q3 2025), and $18.9 million (Q2 2025).